A Benefit-Risk Assessment of Erlotinib in Non-Small-Cell Lung Cancer and Pancreatic Cancer

ISSN： 0114-5916

Source： Drug Safety, Vol.34, Iss.3, 2011-03, pp. : 175-186

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Erlotinib in non-small cell lung cancer: a review

By Blackhall Fiona H Rehman Shazza Thatcher Nicholas

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 6, 2005-06 ,pp. : 995-1002

Informa Healthcare

Access to resources Recommend Favorite

Erlotinib may be an effective therapy for elderly patients with advanced non-small-cell lung cancer

Inpharma, Vol. 1, Iss. 1577, 2007-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Erlotinib Resistance is Altered after Gemcitabine Chemotherapy for Recurrent Non-Small-Cell Lung Cancer

By Wang Yongzheng

Clinical Drug Investigation, Vol. 31, Iss. 4, 2011-04 ,pp. : 279-283

Adis International

Access to resources Recommend Favorite

Cost-effectiveness of Erlotinib versus Docetaxel for Second-line Treatment of Advanced Non-small-cell Lung Cancer in the United Kingdom

By Lewis G Peake M Aultman R Gyldmark M Morlotti L Creeden J de la Orden M

The Journal of International Medical Research, Vol. 38, Iss. 1, 2010-01 ,pp. : 9-21

Field House Publishing

Access to resources Recommend Favorite

Reviewing the safety of erlotinib in non-small cell lung cancer

By Reck Martin Mok Tony Wolf Jürgen Heigener David Wu Yi-long

Expert Opinion on Drug Safety, Vol. 10, Iss. 1, 2011-01 ,pp. : 147-157

Informa Healthcare

Access to resources Recommend Favorite